Trial Profile
A randomised multicentre phase III prospective open-label trial of pre-operative bevacizumab (Avastin) in combination with neo-adjuvant chemotherapy for early breast cancer patients
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 02 Nov 2022
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Cyclophosphamide; Docetaxel; Epirubicin; Fluorouracil
- Indications Ductal carcinoma; Early breast cancer
- Focus Therapeutic Use
- Acronyms ARTemis
- 27 Apr 2017 Results assessing disease-free and overall survival at 3.5 years, published in the Annals of Oncology
- 07 Jun 2016 Results assessing the disease-free survival and overall survival in female patients with HER2 negative early breast cancer presented at the 52nd Annual Meeting of the American Society of Clinical Oncology.
- 06 Oct 2015 Status changed from active, no longer recruiting to completed as reported by ISRCTN: Current Controlled Trials record.